Sonnet BioTherapeutics Holdings, Inc. has announced an expansion of its Phase 1 SB101 clinical trial of SON-1010, a candidate immunotherapy, to evaluate its effectiveness in combination with the ...

WEST LAFAYETTE, Ind. – A multidisciplinary team of researchers led by Steve Son, a professor of mechanical engineering at Purdue University, has received a $7.5 million grant by the Air Force Office ...

PRINCETON, NJ / ACCESSWIRE / February 1, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has ...

Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline ...

Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2 ...